ARTICLE
6 February 2024

Holland & Knight Health Dose: January 30, 2024

HK
Holland & Knight
Contributor
Holland & Knight is a global law firm with nearly 2,000 lawyers in offices throughout the world. Our attorneys provide representation in litigation, business, real estate, healthcare and governmental law. Interdisciplinary practice groups and industry-based teams provide clients with access to attorneys throughout the firm, regardless of location.
Holland & Knight Health Dose is an in-depth weekly dose of legislative and regulatory insights to keep stakeholders abreast of happenings in Washington, D.C., impacting the health sector.
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

Holland & Knight Health Dose is an in-depth weekly dose of legislative and regulatory insights to keep stakeholders abreast of happenings in Washington, D.C., impacting the health sector.

This week's topics include:

  • FY 2024 Appropriations Agreement Reached
  • Senate Finance Committee White Paper Proposes Bonus Payments to Hospitals for Drug Shortage Prevention Measures
  • Prior Authorization Legislation Likely to be Reintroduced Following CMS Final Rule
  • MA Continues to Garner Attention from Congress and CMS
  • Legislation to Permanently Extend Telehealth Flexibilities Reintroduced in Senate
  • Senators Push for New Federal AI Agency to Centralize Regulation of Digital Platforms
  • Drug Manufacturing CEOs Agree to Testify at Senate HELP Committee Hearing on Drug Costs
  • Key House Panel to Hold Hearing on Federal Healthcare Spending
  • Bipartisan Congressional Digital Health Caucus Launch
  • Retirements
  • MACPAC Holds January Public Meeting; Approves Seven Recommendations to Congress
  • MedPAC and MACPAC Release Data Book on Dually Eligible Beneficiaries
  • HRSA Launches New National Maternal Health Initiative
  • New NIH Women's Health Office of Autoimmune Disease Research to Host Roundtables
  • FDA Reorganizes to Establish "Super Office" on Medical Device Cybersecurity and Digital Health
  • CMS to Issue Initial Offers for First Round of Medicare Drug Cost Negotiation Program Selected Drugs
  • FDA Seeks Nominees for Gene Therapy Committee
  • NSF to Launch National AI Research Pilot
  • HHS Releases New Cybersecurity Performance Goals
  • No Surprises Act Suit Given Partial Revival
  • Fourth Circuit Tests Meaning of New Drug for Rebate Program,ChevronDeference Dispute
  • DOJ Investigates AI Tools, References Pharmaceutical Company Case

Read the full Health Dose»

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

ARTICLE
6 February 2024

Holland & Knight Health Dose: January 30, 2024

United States Food, Drugs, Healthcare, Life Sciences
Contributor
Holland & Knight is a global law firm with nearly 2,000 lawyers in offices throughout the world. Our attorneys provide representation in litigation, business, real estate, healthcare and governmental law. Interdisciplinary practice groups and industry-based teams provide clients with access to attorneys throughout the firm, regardless of location.
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More